---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-275976"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-06-18T20:35:15+00:00"
generated_at: "2026-06-18T20:37:00.655231+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics stockholders elect four Class II directors, ratify auditor at 2026 annual meeting

## Summary
- David Zaccardelli, Katie Ellias, David Link, and Andrew Moin elected as Class II directors with 48.3M, 48.3M, 44.1M, and 44.2M votes for, respectively.
- EisnerAmper LLP ratified as independent auditor for FY2026: 59.3M votes for, 3,373 against, 26,798 abstentions.
- Quorum of 59.3M shares (76.12% of outstanding) present at June 18, 2026 meeting.
- Broker non-votes of 10,994,436 on director elections.

## SEC filing metadata
- accession: 0001193125-26-275976
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-06-18T20:35:15+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/0001193125-26-275976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/sabs-20260618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-275976
- JSON: https://secwatch.observer/filing/0001193125-26-275976.json
- Plain text: https://secwatch.observer/filing/0001193125-26-275976.txt

## Key facts
- Shareholder Votes
  SAB Biotherapeutics, Inc. shareholders approved Election of Dr. David Zaccardelli, Pharm.D., Katie Ellias, David Link, MBA, and Andrew Moin, as Class II directors to serve for a term of three years at the 2026-06-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Proposal 1 : Election of four Class II directors Director Votes For Withheld Broker Non-Votes David Zaccardelli, Pharm.D. 48,352,114 2,984 10,994,436 David Link, MBA 44,083,923 4,271,175 10,994,436 Katie Ellias 48,350,086 5,012 10,994,436 Andrew Moin 44,157,704 4,197,394 10,994,436
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/0001193125-26-275976-index.htm
- Shareholder Votes
  SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 at the 2026-06-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Proposal 2: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Abstentions 59,319,363 3,373 26,798
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/0001193125-26-275976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.